Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 8Sarcoma 4Lymphoid 2Other hematologic neoplasm 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 13Zollinger-Ellison Syndrome 2Vipoma 2Somatostatinoma 2Pheochromocytoma 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Neuroendocrine 2Carcinoma, Medullary 2Carcinoid Tumor 2Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Gastrinoma 1Frailty 1Extrapancreatic Neuroendocrine Tumor 1Carcinoma, Merkel Cell 1Adrenal Cortex Neoplasms 1

Interventions

Everolimus 2trifluridine tipiracil drug combination 1pegfilgrastim 1gallium Ga 68 dotatate 1fosbretabulin 1dactolisib 1Temozolomide 1TH 302 1Sunitinib 1Nivolumab 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Temozolomide × NET × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡